Pure Bioscience, Inc. (PURE) Reports Q3 EPS of $0.00
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
December 15, 2025 4:05 PM ESTEL CAJON, Calif.--(BUSINESS WIRE)-- PURE Bioscience, Inc. (OTCQB: PURE) (PURE, the Company or we), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal... More
